PD-L1 and PVR Biomarker Panel for NSCLC Immunotherapy Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting therapeutic responses to cancer immunotherapy, particularly PD-1 blockage for non-small lung cancer, are inadequate due to the dynamic and spatial nature of PD-L1 expression, leading to inaccurate predictions and potential adaptive immune resistance, with existing biomarkers like PD-L1 showing low accuracy and variability.
Innovation Solution
The use of PD-L1 and PVR expression levels as biomarkers to predict therapeutic responses to cancer immunotherapy, including anti-PD-1 and anti-TIGIT therapies, by measuring their levels in biological samples such as tumor tissue, blood, or plasma, allowing for personalized treatment strategies based on specific expression patterns.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If PD-L1 expression level is used as a biomarker to predict therapeutic response to PD-1 blockage, then treatment selection can be guided, but the prediction accuracy is insufficient due to dynamic and spatial variability of PD-L1 expression
Solution Approach 1:
The patent combines multiple biomarkers (PD-L1, PVR, and other immune checkpoint molecules) into a composite prediction system. By measuring and integrating expression levels of multiple markers simultaneously, the system overcomes the limitations of single-marker variability and achieves more stable and accurate prediction of therapeutic response to PD-1 blockage.
Solution Approach 2:
The patent expands the prediction parameters from single biomarker (PD-L1) to multiple biomarkers including PVR and other immune checkpoint molecules. This parameter expansion allows the system to capture the dynamic and spatial variability of immune response by monitoring multiple molecular indicators rather than relying on the fluctuating expression of a single marker.
2Measurement precision
If multiple biomarkers are measured to improve prediction accuracy, then therapeutic response prediction is enhanced, but the complexity of the testing system increases
Solution Approach 1:
The patent employs a multi-functional testing system that can simultaneously detect and quantify multiple biomarkers (PD-L1, PVR, and other immune checkpoint molecules) using a single integrated assay platform. This universal approach allows the system to perform multiple measurement functions in one test, improving prediction accuracy while minimizing the increase in operational complexity.
Solution Approach 2:
The patent merges multiple individual biomarker assays into a single combined testing panel. By integrating the detection of PD-L1, PVR, and other immune checkpoint molecules into one unified test system, the patent reduces the need for separate testing procedures, thereby enhancing prediction accuracy without proportionally increasing system complexity.
3Adaptability or versatility
If PD-L1 blockage therapy is administered to patients with low PD-L1 expression, then treatment options are expanded, but the risk of adaptive immune resistance increases
Solution Approach 1:
The patent performs preliminary assessment of multiple biomarkers (PD-L1, PVR, and other immune checkpoint molecules) before initiating PD-1 blockage therapy. By evaluating the expression levels of these markers in advance, the system predicts potential adaptive immune resistance risks and allows clinicians to select alternative treatment strategies beforehand, thereby expanding treatment options while maintaining reliable therapeutic outcomes.
Solution Approach 2:
The patent establishes a feedback mechanism where the expression levels of multiple biomarkers are continuously monitored to assess the likelihood of adaptive immune resistance. This feedback information guides treatment selection and adjustment, allowing the system to expand treatment options for patients with low PD-L1 expression while maintaining high reliability by avoiding treatments predicted to induce resistance.
Data Source
AI summary
Provided in the present disclosure are a method for providing information on a therapeutic reaction of cancer immunotherapy and a kit using same for providing information, the method comprising the steps of: measuring respective expression levels of PD-L1 and PVR in a biological sample isolated from a subject; and evaluating the therapeutic reaction of cancer immunotherapy for the subject on the basis of the measured expression levels of PD-L1 and PVR.